Procaps (PROC) Company Sales Revenue

Geopolitical risks and raw material supply disruptions are creating volatility, which is reflected in the total sales revenue of Procaps Group S.A. (PROC) on this GURU.Markets chart, where the value of 0.00 serves as the baseline indicator. Stability is provided by automated capsule production plants that minimize defects, as well as a flawless reputation as a reliable B2B partner in the eyes of global pharmaceutical behemoths.

PROC (Procaps Group Corp) Company Revenue history from 07/04/2022 to 02/16/2025

Comprehensive metric breakdowns and analytics for Procaps (PROC)

- market price and analyst price targets:

Market Price Procaps Group Corp|PROC - Price Target Chart

- market capitalization details:

Market Value Procaps Group|PROC - Total Company Value

- balance sheet net asset value indicators:

Share Book Value Procaps|PROC - Company Book Value|Market Value to Book Value procapsgroup.com|PROC - Aggregate Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

PROC - Net Income|Expected Net Income Procaps Group S.A.|PROC - P/E Multiple|Forward Price to Earnings Multiple procapsgroup.com|PROC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Procaps Group|PROC - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Procaps|PROC - Net earnings per share for the last 12 months|Quarterly EPS earnings growth procapsgroup.com|PROC - Earnings per share growth in current year|Net earnings per share change forecast for next year Procaps Group S.A.

- sales volume and revenue indicators:

PROC - Company Sales|Company Future Revenue Procaps Group Corp|PROC - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Procaps Group

Summary company analysis:PROC, Procaps Group Corp

Procaps Group S.A. measures sales as the actual cash inflow from product realization, reflecting the efficiency of business plan execution and the stability of the operating cycle. For Procaps Group S.A., the sales figure confirms the commercialization of innovations in drug bioavailability and production automation, where steady revenue growth indicates high-quality management of scientific resources and assets.

Analysis of competing companies